Mesenchymal stem cells improve mouse non-heart-beating liver graft survival by inhibiting Kupffer cell apoptosis via TLR4-ERK1/2-Fas/FasL-caspase3 pathway regulation by Yang Tian et al.
RESEARCH Open Access
Mesenchymal stem cells improve mouse
non-heart-beating liver graft survival by
inhibiting Kupffer cell apoptosis via TLR4-
ERK1/2-Fas/FasL-caspase3 pathway
regulation
Yang Tian1†, Jingcheng Wang1†, Wei Wang1, Yuan Ding2, Zhongquan Sun2, Qiyi Zhang2, Yan Wang1,
Haiyang Xie2,3, Sheng Yan1,2,3* and Shusen Zheng1,2,3*
Abstract
Background: Liver transplantation is the optimal treatment option for end-stage liver disease, but organ shortages
dramatically restrict its application. Donation after cardiac death (DCD) is an alternative approach that may expand
the donor pool, but it faces challenges such as graft dysfunction, early graft loss, and cholangiopathy. Moreover,
DCD liver grafts are no longer eligible for transplantation after their warm ischaemic time exceeds 30 min.
Mesenchymal stem cells (MSCs) have been proposed as a promising therapy for treatment of certain liver diseases,
but the role of MSCs in DCD liver graft function remains elusive.
Methods: In this study, we established an arterialized mouse non-heart-beating (NHB) liver transplantation model,
and compared survival rates, cytokine and chemokine expression, histology, and the results of in vitro co-culture
experiments in animals with or without MSC infusion.
Results: MSCs markedly ameliorated NHB liver graft injury and improved survival post-transplantation. Additionally, MSCs
suppressed Kupffer cell apoptosis, Th1/Th17 immune responses, chemokine expression, and inflammatory cell infiltration. In
vitro, PGE2 secreted by MSCs inhibited Kupffer cell apoptosis via TLR4-ERK1/2-caspase3 pathway regulation.
Conclusion: Our study uncovers a protective role for MSCs and elucidates the underlying immunomodulatory mechanism
in an NHB liver transplantation model. Our results suggest that MSCs are uniquely positioned for use in future clinical
studies owing to their ability to protect DCD liver grafts, particularly in patients for whom DCD organs are not an option
according to current criteria.
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Background
Liver transplantation was first introduced by Dr. Starzl
over five decades ago, and is still considered to be the
optimal treatment for end-stage liver disease [1]. This
procedure is currently accepted and performed by many
transplant centres worldwide, but organ shortages
remain a prevalent problem [2] which is reflected in the
median time to transplant among waiting-listed candi-
dates. For example, in the United States, the median
time increased from 14.8 months in 2004 to 19.5 months
in 2011 [3]. As a result, death rates among patients on
the waiting list have increased over the past two decades
[2]. Therefore, donation after cardiac death (DCD),
which would expand the pool of available donors, has
been proposed as an alternative to ameliorate the organ
shortage crisis. In the United States, the percentage of
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DCD organs has grown annually from 1% in 1996 to 10%
in 2007 [4]. However, liver graft ischaemia/reperfusion
injury (IRI) during DCD donation is inevitable, and the in-
cidence of primary graft dysfunction, early graft loss, and
cholangiopathy is fairly high [5–9]. Evidence-based medi-
cine has demonstrated the relatively good quality and safety
of DCD grafts with a warm ischaemic time of less than
30 min, and this criterion is implemented in transplantation
centres worldwide. For grafts with warm ischaemic time
less than 30 min, the primary negative outcome of DCD
liver transplantation is late ischaemic cholangiopathy rather
than primary non-function, whereas for grafts with warm
ischaemic time over 30 min, the primary negative outcome
of DCD liver transplantation is early mortality. Numerous
studies have been carried out in recent years to identify
novel strategies to alleviate DCD liver graft injury.
Mesenchymal stem cells (MSCs) are multipotent cells
that are capable of differentiating into specific osteoblastic,
adipogenic, and chondrogenic lineages [10]. With the de-
velopment of regenerative and translational medicine,
MSCs have become a subject of research interest because
of their low immunogenicity and immunomodulatory
properties [11]. MSCs exert powerful immunosuppressive
functions via paracrine effects and cell–cell contact-
dependent interactions, and MSCs also inhibit the
proliferation of activated lymphocytes, thereby providing
survival signals to resting immune cells and subsequently
stimulating the induction of regulatory immune cells [12].
Among various soluble mediators, inducible nitric oxide
synthase (iNOS), transforming growth factor (TGF)β,
indoleamine 2,3-dioxygenase (IDO), and prostaglandin E2
(PGE2) are the primary factors responsible for the thera-
peutic potential of MSCs [13]. Recently, MSCs have been
applied to treat autoimmune diseases, diabetes, liver dis-
eases such as fibrosis, non-alcoholic fatty liver cirrhosis,
fulminant hepatic failure, and solid organ transplantation
[14–18]. However, it is unclear whether MSCs effectively
protect DCD liver grafts, and the mechanisms underlying
this hypothetical protection remain unknown.
The mouse orthotopic liver transplantation model has
unique advantages over rat or swine models, owing to
the well-characterized mouse genome and the wide-
spread availability of genetic modification techniques,
thus making it a powerful research tool to investigate
liver biology, transplant immunology, and DCD-related
IRI [19]. However, no optimal mouse non-heart-beating
(NHB) liver transplantation model for DCD research has
been reported. In this study, we established a standard
arterialized mouse NHB liver transplantation model and
explored the optimal conditions for NHB modelling.
Using this model, we provide the first demonstration of
the ability of MSCs to effectively ameliorate NHB-
induced graft injury and significantly improve recipient
survival by inhibiting Kupffer cell apoptosis. In addition,
this study highlights the importance of Kupffer cells in
the protective effects exerted by MSCs on NHB liver
grafts. Furthermore, MSC-mediated protection against
Kupffer cell apoptosis is primarily facilitated by secreted





b) and CBF1 (H2
bd) mice aged 8–12
weeks were purchased from the Model Animal Research
Center of Nanjing University. All mice were maintained
in autocephalous individually ventilated cages (IVC) in a
specific-pathogen-free environment and given standard
laboratory chow and tap water ad libitum. Animal
feeding practices and all experiments involving animals
were conducted in accordance with the Guidelines for
the Care and Use of Laboratory Animals and received
the approval of the Animal Ethics Committees of
Zhejiang University (Hangzhou, China).
Establishment of an arterialized mouse NHB liver
transplantation model
C57Bl/6 mice were used as donors, and CBF1 mice were
used as recipients. Mouse NHB orthotropic liver trans-
plantation was performed by two licensed animal
surgeons using the “double cuff” method, as described in
previous studies [20, 21], and the hepatic artery was re-
constructed via an aortic trunk method [22]. Briefly,
each donor was injected with 100 IU heparin via the tail
vein under inhalation anaesthesia. Then, a cross incision
was made to expose the donor liver, and the ligaments
around the liver were dissected. CO2 asphyxiation was
administered. NHB timing began when cardiac arrest
was confirmed by palpation. After NHB time at 0 min,
5 min, 10 min and 20 min, liver grafts were perfused
with cold University of Wisconsin perfusate, harvested
with the hepatic–celiac axis–aortic artery segment, and
preserved in UW solution at 4 °C. The suprahepatic in-
ferior vena cava was connected using a continuous su-
ture approach, and the portal vein and the infrahepatic
inferior vena cava were reconstructed via the “double
cuff” method. The common bile duct was connected
with a biliary stent. Subsequently, portal vein com-
mencement was carried out at a cold ischaemic time of
120 min. To perform artery reconstruction, the hepatic–
celiac axis–aortic artery segment was anastomosed to the
recipient aorta by using an “end-to-side anastomosis”
technique involving interrupted sutures. Because surgical
fault may lead to uncontrolled arterial bleeding or
thrombus and result in recipient death, only recipients
with perfect hepatic arteriopalmus and without unex-
pected bleeding were included into our experiments to
avoid any surgical influence on recipient survival. After
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transplantation, all recipients received subcutaneous injec-
tions of saline and antibiotics and were maintained in a
temperature-controlled IVC unit with a 12 h light–dark
cycle and given free access to standard laboratory chow
and tap water. Recipient survival was observed and re-
corded every 6 h.
Isolation, culture, and retroviral transduction of
immortalized T40-MSCs
Immortalized T40-MSCs originally isolated from the
bone marrow of C57Bl/6 mice were a kind gift from
Prof. Weimin Fan of Zhejiang University. In brief, a male
8-week-old C57Bl/6 mouse was sacrificed, and whole
bone marrow was retrieved by flushing the bones with
Dulbecco’s modified Eagle’s medium (DMEM; GIBCO,
Waltham, MA, USA). All bone marrow cells were cul-
tured in DMEM with 10% foetal bovine serum (FBS;
GIBCO) for 48 h. Non-adherent haematopoietic cells
were discarded. Adherent cells were then washed three
times with phosphate-buffered saline (PBS) and replen-
ished with 15 mL fresh DMEM containing 10% FBS.
When the cells grew to 60% confluence, they were trans-
fected with a T40-expressing retroviral vector.
To achieve T40-expressing retrovirus packaging,
HEK293 cells were plated at a cell density of approxi-
mately 50%. After 3–5 h, the cells were transfected with
250 μL Opti-MEM plus 37.5 μL of a solution containing
15 μL Lipofect AMINE (Invitrogen, Waltham, MA,
USA), 7.5 μL of the packaging plasmid pAmpho and
15 μL pSSRV60-T40. The medium was discarded 3–5 h
later and replaced with 4 mL fresh complete DMEM.
Retrovirus-containing supernatants were collected at 36,
60, and 84 h. The generated virus was kept at 4 °C or
directly used to infect MSCs. Immortalized T40–MSCs
were generated by transducing MSCs twice per day for 2
consecutive days. Hygromycin B (0.2 mg/mL; Sigma-
Aldrich, St. Louis, MO, USA) selection began at the end
of the second round of infection.
Differentiation and identification of MSCs
Adipogenic and osteogenic differentiation were induced
in vitro, and MSC identification was carried out. To
achieve adipogenic differentiation, MSCs were cultured
with 1 μM dexamethasone and 0.2 mM indomethacin in
DMEM plus 10% FBS, and the conditional medium was
changed every other day. After 7 days, adipocytic differ-
entiation was examined through oil red O staining.
Osteogenic MSC differentiation was performed with
conditional medium containing 100 mM dexametha-
sone, 10 mM β-glycerophosphate disodium, and 50 μM
L-ascorbic acid-2-phosphate. The medium was changed
every other day, and 2 weeks later MSCs were stained
with alizarin red to examine calcium deposition. All
conditional medium supplements were purchased from
Sigma-Aldrich.
MSC infusion and GdCl3 administration
MSCs in the logarithmic phase were trypsinised and
suspended in DMEM at a concentration of 5 × 107/mL.
After portal vein commencement, a 20-μL suspension con-
taining 106 MSCs was injected intrasplenically. Electro-
coagulation was applied at the puncture point to stop
bleeding. In other experiments, 20 mg/Kg gadolinium
chloride (GdCl3; Sigma-Aldrich) solution was administered
intraperitoneally to donor C57Bl/6 mice 24 h before
transplantation to eliminate intrahepatic Kupffer cells.
Liver function test and histological evaluation
Under inhalation anaesthesia, blood was collected from
the inferior vena cava, and serum alanine aminotransfer-
ase (ALT) and aspartate aminotransferase (AST) were
measured using an automatic biochemical analyser in
the clinical laboratory of our hospital. Liver grafts were
harvested, formalin-fixed, sectioned, and stained with
haematoxylin and eosin for histopathological evaluation
using the Suzuki Score System (Table 1). Each graft
section was examined in a blinded fashion by an experi-
enced pathologist.
Quantitative real-time polymerase chain reaction
The mRNA levels of cytokines and chemokines were
detected by quantitative real-time polymerase chain
reaction (RT-PCR), as described in our previous study
[20, 23]. Briefly, total RNA was extracted from frozen
grafts by using TRIzol reagent (Invitrogen) and then
reverse-transcribed into cDNA using a reverse transcript-
ase kit (Bio-Rad, Hercules, CA, USA). cDNA primers and
iTaq Universal SYBR Green Supermix (Bio-Rad) were
added to PCR plates, and PCR was carried out with an
Applied Biosystems 7900 PCR System. Relative mRNA
quantification was performed using the 2−△△Ct method ac-
cording to the manufacturer’s manual. Gene-specific
primers are shown in Table 2.
Immunofluorescence and terminal deoxynucleotidyl
transferase dUTP nick end labelling (TUNEL) detection
For immunofluorescence analysis, frozen sections of
liver graft specimens were incubated with anti-mouse
Table 1 Standards of Suzuki score for liver injury
Score Congestion Vacuole degeneration Necrosis
0 None None None
1 Slight Slight Single cell
2 Mild Mild <30%
3 Moderate Moderate 31–60%
4 Severe Severe >60%
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F4/80-FITC (Abcam, Cambridge, MA, USA) at 4 °C
overnight.
Proliferating Kupffer cells in frozen graft sections were
stained with anti-mouse F4/80-Alexa Flour 647 (Abcam)
and anti-Ki67 antibodies (Abcam) at 4 °C overnight. Sec-
tions were then incubated with a goat-anti-rat IgG-Alexa
Flour 488 secondary antibody (Abcam) for 2 h at room
temperature.
Apoptotic Kupffer cells in frozen graft sections were
stained with anti-mouse F4/80-Alexa Flour 647 (Abcam)
and detected in a TUNEL assay with an ApopTag® Plus
Peroxidase in Situ Apoptosis Kit (EMD Millipore,
Darmstadt, Germany). Detection and all measurements
were carried out following the manufacturer’s instructions.
All of the sections were then mounted in Mounting
Medium with DAPI (Vector Laboratories, Burlingame,
CA, USA) and scanned with a two-photon laser confocal
microscope (Olympus, Tokyo, Japan).
Immunohistochemistry staining
For immunohistochemistry staining, antigen retrieval
and goat serum blocking were first performed, and then
paraffin-embedded graft sections were incubated with
anti-myeloperoxidase (MPO; Abcam) and anti-CD3
(R&D, Minneapolis, MN, USA) at 4 °C overnight. Sec-
tions were then incubated with a goat-anti-rabbit or
goat-anti-rat IgG secondary antibody conjugated to
horseradish peroxidase for 2 h at room temperature
(Invitrogen). 3,3′-diaminobenzidine peroxidase substrate
was used as a detection reagent (Vector Laboratories).
All sections were visualized using BX41 microscopy
(Olympus).
Immunoassay and MPO measurement
Serum cytokine and chemokine protein levels were mea-
sured with a Luminex-200 system using the ProcartaPlex
Mouse Cytokine & Chemokine Panel Kit (eBioscience,
San Diego, CA, USA), and serum MPO activity was
measured using an MPO Activity Colorimetric Assay Kit
(Biovision, Milpitas, CA, USA). Detection and all mea-
surements were carried out following the manufacturer’s
instructions.
MSC–macrophage in vitro co-culture
In vitro experiments were carried out using the mouse-
derived RAW264.7 cell line, which was purchased from
the Chinese Academy of Sciences, to represent Kupffer
cells. Generally, 5 × 105 macrophages per well were
seeded in a six-well plate, and 105 MSCs were seeded in
a 0.4-μm polycarbonate membrane insert Transwell
(Corning, Corning, NY, USA) in medium containing or
lacking NS-398 (5 μM; Sigma-Aldrich). After 24 h, the
medium was changed once to remove non-adherent
dead cells. After 2 h of incubation at 37 °C without O2,
the macrophages were transferred into co-culture with
the Transwells containing MSCs, and 0, 100, 200, 400,
or 800 μM hydrogen peroxide (H2O2) was added to spe-
cific wells. Then, the co-cultured cells were incubated at
37 °C with 5% CO2 for 6 h to mimic the process of IRI
during NHB liver transplantation in vivo.
Flow cytometry to detect co-cultured macrophage
apoptosis
After 6 h of co-culture, all macrophages were collected for
early apoptosis detection by flow cytometry using an
Annexin V-FITC/PI apoptosis detection kit (DOJINDO,
Kumamoto, Japan) according to the manufacturer’s manual.
Western blotting
The expression of specific target proteins was examined by
Western blotting, as described in our previous study [23].
Total protein fractions from co-cultured macrophages were
extracted with RIPA and protease and phosphatase
inhibitor cocktail (Thermo Fisher, Waltham, MA, USA).
Anti-TLR2 (Epitomics, Cambridge, MA, USA), anti-TLR4
(Abcam), anti-ERK1/2 (Cell Signaling Technology, Danvers,
MA, USA), anti-pERK1/2 (Cell Signaling Technology),
anti-Fas (Biovision, Milpitas, CA, USA), anti-FasL (Biovi-
sion), anti-cleaved caspase3 (Cell Signaling Technology),
and anti-β-actin (Abcam) antibodies were incubated with
Table 2 Sequences of primers used in quantitative RT-PCR
Gene Sequences Length (base)
β-actin Forward: CATTGCTGACAGGATGCAGAAGG 23
Reverse: TGCTGGAAGGTGGACAGTGAGG 22
IL1α Forward: ACGGCTGAGTTTCAGTGAGACC 22
Reverse: CACTCTGGTAGGTGTAAGGTGC 22
IL1β Forward: TGGACCTTCCAGGATGAGGACA 22
Reverse: GTTCATCTCGGAGCCTGTAGTG 22
IL2 Forward: GCGGCATGTTCTGGATTTGACTC 23
Reverse: CCACCACAGTTGCTGACTCATC 22
IL4 Forward: ATCATCGGCATTTTGAACGAGGTC 24
Reverse: ACCTTGGAAGCCCTACAGACGA 22
IL6 Forward: TACCACTTCACAAGTCGGAGGC 22
Reverse: CTGCAAGTGCATCATCGTTGTTC 23
IL10 Forward: CGGGAAGACAATAACTGCACCC 22
Reverse: CGGTTAGCAGTATGTTGTCCAGC 23
TNFα Forward: GGTGCCTATGTCTCAGCCTCTT 22
Reverse: GCCATAGAACTGATGAGAGGGAG 23
IFNγ Forward: CAGCAACAGCAAGGCGAAAAAGG 23
Reverse: CAGCAACAGCAAGGCGAAAAAGG 23
F4/80 Forward: CGTGTTGTTGGTGGCACTGTGA 22
Reverse: CCACATCAGTGTTCCAGGAGAC 22
IFN interferon, IL interleukin, RT-PCR real-time polymerase chain reaction, TNF
tumour necrosis factor
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macrophage protein-containing nitrocellulose membranes
overnight. A ChemiDoc Imaging System was used to de-
velop the images (Bio-Rad, Hercules, CA, USA). Grey
values were calculated and analysed for each band with
ImageLab software (Bio-Rad).
Statistics
Recipient survival was expressed graphically using the
Kaplan–Meier method. All other data are presented as
the mean ± SEM and were analysed using GraphPad
Prism 5.0.1 software (GraphPad Prism Software Inc., La
Jolla, CA, USA). A log-rank (Mantel-Cox) test was used
for survival rate analysis, and Student’s t test was applied
to assess data obtained from different groups. Two-sided
P < 0.05 was considered to be statistically significant.
Results
NHB time extension reduces the survival rate with
aggravated liver graft injury
To establish an optimal mouse model for NHB liver
graft research, arterialized orthotopic liver transplanta-
tions were performed, and different NHB timing options
were tested. Sham operations were carried out as normal
controls. For the NHB0min group, all recipients survived
more than 14 days post-transplantation. Only 75% of re-
cipients survived at 14 days in the NHB5min group, and
the 14-day survival rate was reduced to 37.5% and 12.5%
in the NHB10min group and NHB20min group, respect-
ively, thus revealing the increased incidence of primary
graft dysfunction and early graft dysfunction with NHB
time extension (Fig. 1a). Serum levels of ALT/AST, the
most sensitive IRI indicator in liver grafts, rise rapidly
once reperfusion begins and reach a peak at 6 h post-
transplantation. Afterwards, the liver graft initiates cer-
tain mechanisms to repair IRI and hepatocellular dam-
age, and serum ALT/AST levels decrease gradually.
However, if IRI is too severe for the graft to repair itself,
liver dysfunction occurs within several days, ultimately
resulting in recipient death [24–26]. To evaluate liver
graft injury, serum and liver specimens were collected
and examined at 6 h post-transplantation when inflam-
mation peaked. A gradual increase in serum ALT and
AST levels was detected in these groups (Fig. 1b and c).
Histopathological examination indicated 30% hepatocel-
lular oedema with mild inflammatory cell infiltration in
the NHB0min group, 60% hepatocellular oedema with
widened hepatic sinusoids in the NHB5min group, severe
hepatocellular oedema with spotty necrosis in the
Fig. 1 Non-heart-beating (NHB) time extension reduces the survival rate with aggravated liver graft injury. Arterialized C57Bl/6-CBF1 liver transplantations
were performed with 0 min, 5 min, 10 min, and 20 min of NHB time, and 120 min of cold ischaemic time, respectively. a Cumulative recipient survival
rates were analysed. Results of four independent experiments were combined (N= 8 for each group). Log-Rank (Mantel-Cox) test was used for comparison
of different survival curves. *P< 0.05, **P< 0.01, ***P< 0.001. Serum b alanine aminotransferase (ALT) and c aspartate aminotransferase (AST) levels from each
group were tested at 6 h post-transplantation (N= 6 for each group). d Liver grafts were sectioned for histological examination. Representative images
from one experiment are shown at 400× magnification. e Suzuki scores of each section were evaluated by an experienced pathologist in a blinded fashion
(N= 6 for each group). b, c, e Results are presented as mean ± SEM for each group. *P< 0.05, **P< 0.01, ***P< 0.001. NS not significant
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NHB10min group, and patchy necrosis accompanied by
severe inflammatory cell infiltration and widened sinu-
soids in the NHB20min group (Fig. 1d). These results
were consistent with a clear increase in the Suzuki
scores of the liver grafts (Fig. 1e). Together, these data
suggested that NHB time extension aggravated liver graft
injury, resulting in a dramatic reduction in the survival
rate after liver transplantation.
Impaired Th1/Th2 responses and Kupffer cells after NHB
liver transplantation
Th1 (tumour necrosis factor (TNF)α, interferon (IFN)γ,
and interleukin (IL)2) and Th17 (IL17) cytokines are pro-
inflammatory during pathogenesis, whereas Th2 cytokines
(IL4, IL6, and IL10) exert immunomodulatory functions
that inhibit severe inflammation in the body. Given the
critical role of Th1/Th2 immune responses in liver self-
homeostasis during pathological events [27], the intrahepa-
tic mRNA expression of classical Th1/Th2 cytokines was
determined by performing quantitative RT-PCR. Unexpect-
edly, Th1 and Th2 cytokine mRNA levels did not increase
with aggravated liver graft injury when NHB time was ex-
tended. In contrast, with the exception of IL2 and IL4, the
mRNA expression of all other Th1 and Th2 cytokines, in-
cluding TNFα, IFNγ, IL6, and IL10, was downregulated,
thus indicating the impairment of intrahepatic Th1/Th2 cell
responses after NHB liver transplantation (Fig. 2a and b).
Kupffer cells are very sensitive to pathological factors dur-
ing IRI, and initiate Th1/Th2 responses by secreting certain
cytokines and chemokines. To investigate Kupffer cell sta-
tus in the context of Th1/Th2 response impairment, we
first detected the intrahepatic mRNA expression of F4/80, a
classic surface marker of Kupffer cells [28]. As expected,
F4/80 mRNA levels decreased robustly as NHB time was
extended (Fig. 2c). Similarly, immunofluorescence staining
of frozen grafts showed a dramatic loss of F4/80-positive
Kupffer cells within different groups (Fig. 2d and e). Thus,
as NHB time was extended, aggravated liver IRI led to a
dramatic loss of Kupffer cells and impaired Th1/Th2 im-
mune responses post-transplantation.
In addition, we compared survival rates, ALT and AST
levels, and graft histopathological injury in different
NHB groups and determined the optimal conditions for
the mouse arterialized NHB liver transplantation model
to be an NHB time of 10 min and a cold ischaemic time
of 120 min; under these conditions, any effects of vari-
ous interventions were conveniently observed as changes
in recipient survival.
MSCs ameliorate NHB-induced graft injury and increase
the recipient survival rate
We evaluated the adipogenic and osteogenic differenti-
ation potential of MSCs in conditioned medium in vitro.
Intra-MSC lipid droplets stained with oil red O [29] and
calcium deposition stained with alizarin red S were
clearly observed (Fig. 3a) [30].
To examine the role of MSCs in mouse NHB liver
transplantation, MSCs were slowly intrasplenically in-
fused after portal vein commencement; under these con-
ditions, the majority of MSCs gradually migrate into the
hepatic sinusoids through the portal vein and avoid por-
tal vein embolization [31–33]. MSC infusion effectively
improved the survival rate post-transplantation, with
100% survival of recipients by day 14, compared with
37.5% survival in the NHB10min group (Fig. 3b), a result
consistent with a significant decrease in serum ALT and
AST levels at 6 h post-transplantation (Fig. 3c and d).
Histopathological examination showed normal hepato-
cellular morphology without oedema, vacuolar degener-
ation, or necrosis, and a significant decrease in the
Suzuki scores in the MSC10min group, which significantly
differed from the severe hepatocellular oedema with
spotty necrosis observed in the NHB10min group (Fig. 3e
and f). Thus, MSC infusion significantly ameliorated
warm ischaemia-induced liver graft injury and promoted
recipient survival after NHB liver transplantation.
MSCs protect and restore Kupffer cells by inhibiting
apoptosis but not by promoting proliferation
As mentioned above, Kupffer cells were dramatically im-
paired by extended NHB injury, thus indicating a close
relationship between graft quality and Kupffer cell status.
Because MSCs effectively protect against NHB liver graft
injury, we sought to determine how MSC infusion af-
fects Kupffer cells. To investigate this question, F4/80
mRNA expression and immunofluorescence staining
were evaluated. Interestingly, MSCs significantly im-
proved F4/80 mRNA expression in liver grafts compared
with the NHB10min group (Fig. 4a). Moreover, an obvious
increase in F4/80-positive cells was detected using con-
focal microscopy (Fig. 4b and c), thus suggesting the res-
toration of Kupffer cells due to MSC infusion.
However, it is unclear how MSCs promote Kupffer cell
restoration. Thus, in situ proliferating and apoptotic
Kupffer cells were detected by performing Ki67-F4/80
and TUNEL-F4/80 immunofluorescent staining, respect-
ively. Proliferating cells were mainly non-parenchymal
cells in the NHB10min group, while proliferating cells
could seldom be detected in the MSC10min group
(Fig. 4d). However, the percentage of Ki67-positive Kupf-
fer cells showed no difference between these two groups
(Fig. 4e). Meanwhile, sporadic hepatocellular apoptosis
and non-parenchymal cell apoptosis were detected in
the NHB10min group, which was rarely observed in the
MSC10min group (Fig. 4f ). Besides, the percentage of
TUNEL-positive Kupffer cells in the NHB10min group
was significantly higher than in the MSC10min group
(Fig. 4g). These results indicated that MSCs protected
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Kupffer cells by inhibiting their apoptosis but not by
promoting their proliferation. We hypothesized that the
initiation of certain proliferative mechanisms by non-
parenchymal cells might replace specific cells lost due to
apoptosis resulting from severe injury and graft damage
in the NHB10min group. While MSC infusion reversed
the damage caused by IRI, non-parenchymal cells and
hepatocytes rarely showed Ki67 and TUNEL expression.
However, the underlying mechanisms require further
investigation.
MSC-mediated protection of NHB grafts depends on
Kupffer cells
Although we observed a close relationship between MSCs
and Kupffer cells, we lacked more direct evidence. Because
MSCs recruit peripheral lymphocytes into the liver graft by
secreting a series of chemokines, further study is needed to
determine whether the restoration of F4/80+ cells after
MSC infusion is related to peripheral macrophage recruit-
ment. The administration of 20 mg/Kg doses of GdCl3
causes Kupffer cell apoptosis and selectively blocks Kupffer
Fig. 2 Th1/Th2 responses and Kupffer cells are impaired after non-heart-beating (NHB) liver transplantation. At 6 h post-transplantation, liver grafts
from each group were collected for quantitative RT-PCR analysis and immunofluorescence staining. Intrahepatic mRNA levels of a Th1 cytokines
(TNFα, IFNγ, and IL2) and b Th2 cytokines (IL4, IL6, and IL10) in each group were measured by quantitative RT-PCR (N = 8–10 for each group).
c Intrahepatic mRNA level of F4/80 was detected by quantitative RT-PCR (N = 8–10 for each group). d F4/80 immunofluorescence staining of
frozen liver graft tissues were visualized by confocal scanning. Representative images from one experiment are shown at 600× magnification.
e Intrahepatic F4/80-positive cells in each sections were counted for statistical analysis (N = 6 for each group). a, b, c, e Results are presented as
mean ± SEM for each group. *P < 0.05, **P < 0.01, ***P < 0.001. IFN interferon, IL interleukin, TNF tumour necrosis factor
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cell effector functions but does not cause liver parenchymal
cell toxicity [31]. Rather than shortening the survival of
injected mice, the administration of 20 mg/Kg doses of
GdCl3 may protect the liver against IRI [34]. To elucidate
the true role of Kupffer cells in the MSC-mediated protec-
tion of NHB grafts, 20 mg/Kg GdCl3 was applied in NHB
donors 24 h before surgical procedures, so as not to affect
the recipient’s bone marrow-derived macrophage recruit-
ment into the liver graft post-transplantation. After the de-
pletion of intrahepatic Kupffer cells with GdCl3, NHB liver
grafts were transplanted into recipients with simultaneous
MSC infusion. Unexpectedly, the 14-day survival rate dra-
matically decreased to 25% in the GdCl3-pretreated group
(Fig. 3b), and this result was not significantly different from
that observed for the NHB10min group. Thus, the protective
effects of MSCs on NHB liver grafts appear to depend on
Kupffer cells. Furthermore, the restoration of F4/80+ cells
after MSC infusion is dependent on the direct protection of
Kupffer cells against apoptosis, not the recruitment of per-
ipheral macrophages into the liver grafts.
MSCs suppress Th1/Th17 cells but promote IL10 secretion
As mentioned previously, classical cytokines were
investigated to assess Th1/Th2/Th17 responses post-
transplantation. Compared with the NHB10min group,
MSCs together with restored Kupffer cells significantly
decreased serum TNFα, IFNγ, and IL2 protein secretion.
Similarly, the serum protein expression of other pro-
inflammatory cytokines, including IL17, IL1β, and MPO,
was suppressed. MSCs had no effects on Th2 cytokines
such as IL4 and IL6 but clearly promoted IL10 secretion
(Fig. 5a). Thus, MSC infusion suppresses Th1/Th17 im-
mune responses but exerts no effects on Th2 responses
with the exception of IL10 secretion.
MSCs suppress chemokine expression and inflammatory
cell infiltration in liver grafts
Kupffer cells are known as “sensor cells” that respond to
IRI and release different chemokines, which recruit large
amounts of inflammatory cells that infiltrate the liver [35].
The serum protein levels of chemokines were investigated
Fig. 3 Mesenchymal stem cells (MSCs) ameliorate non-heart-beating (NHB)-induced graft injury and increase the recipient survival rate. Arterialized C57Bl/
6-CBF1 liver transplantations were performed with 10 min of NHB time and 120 min of cold ischaemic time, respectively. In the MSC10min group, 10
6 MSCs
were intrasplenically infused post-transplantation. In the MSC10min + GdCl3 group, 20 mg/Kg GdCl3 was intraperitoneally injected 24 h before graft harvest.
a MSCs were stained with red oil O and alizarin red S for adipogenic and osteogenic identification after conditioned differentiation. Undifferentiation:
normal culture medium; Differentiation: conditioned culture medium. Representative images from one experiment out of three are shown at 400×
magnification. b Cumulative recipient survival rates were analysed. Data from three independent experiments are combined (N = 8 for each group).
Log-Rank (Mantel-Cox) test was used for comparison of different survival curves. *P < 0.05, **P < 0.01. Serum c alanine aminotransferase (ALT) and
d aspartate aminotransferase (AST) levels from each group were tested at 6 h post-transplantation (N = 6 for each group). e Liver grafts were sectioned
for histological examination. Representative images from one experiment are shown at 200× and 400× magnification. f Suzuki scores of each section
were evaluated by an experienced pathologist in a blinded fashion (N = 6 for each group). c, d, f Results are presented as mean ± SEM for each group.
*P < 0.05, **P < 0.01. NS not significant
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to evaluate changes resulting from MSC infusion. Interest-
ingly, the serum protein expression of CXCL1, CCL2,
CCL4, CCL7, and CXCL10 was notably suppressed in the
MSC infusion group (Fig. 5b). Intrahepatic infiltrating
cells are indicative of the degree of liver inflammation;
specifically, neutrophils and T cells are the most inform-
ative. Because neutrophils migrate into pathological sites
and release MPO, MPO is regarded as a typical neutrophil
biomarker, whereas CD3 is a classical T-cell biomarker.
We performed immunohistochemical staining to detect
MPO and CD3 to evaluate inflammation in liver grafts.
Intrahepatic infiltration of MPO+ neutrophils and CD3+ T
cells was dramatically decreased (Fig. 5c, d and e). Our re-
sults indicated that Kupffer cell restoration, together with
infused MSCs, suppresses chemokine expression and re-
duces neutrophil and T-cell infiltration into liver grafts
post-transplantation.
MSCs inhibit Kupffer cell apoptosis by secreting PGE2 in
vitro
To clarify the underlying mechanism by which MSCs in-
hibit Kupffer cell apoptosis, we used an in vitro cell–cell
co-culture system with the murine-derived RAW264.7
cell line to represent Kupffer cells, which exclusively ex-
press F4/80 antigen on the membrane surface (Fig. 6a)
[36]. Six hours after hydrogen peroxide (H2O2) stimula-
tion, Kupffer cell apoptosis was elevated in an H2O2
dose-dependent manner compared with that in controls,
whereas co-culture with MSCs protected Kupffer cells
from apoptosis in the presence of low concentrations of
H2O2 (100 μM and 200 μM). NS-398, a specific PGE2
inhibitor, dramatically reversed the reduction in apop-
tosis observed in the presence of MSCs (Fig. 6b and c).
When stimulated with high concentrations of H2O2
(400 μM and 800 μM), MSCs lost their ability to protect
Fig. 4 Mesenchymal stem cells (MSCs) protect and restore Kupffer cells by inhibiting apoptosis but not by promoting proliferation. At 6 h post-
transplantation, liver grafts from each group were collected for quantitative RT-PCR analysis and immunofluorescence staining. a Intrahepatic
mRNA level of F4/80 was detected by quantitative RT-PCR (N = 6 for each group). b F4/80 immunofluorescence staining of frozen liver graft
tissues were visualized by confocal scanning. Representative images from one experiment are shown at 600× magnification. c Intrahepatic F4/80-
positive cells in each section were counted for statistical analysis (N = 6 for each group). d Proliferation of Kupffer cells was detected by Ki67
(green) and F4/80 (red) double staining. Representative images from one experiment are shown at 600× magnification. e The percentage of Ki67+
F4/80+ cells in total F4/80+ Kupffer cells was counted and calculated for statistical analysis (N = 3 for each group). f Apoptosis of Kupffer cells was
detected by TUNEL (green) and F4/80 (red) double staining. Representative images from one experiment are shown at 600× magnification. g The percentage
of TUNEL+ F4/80+ cells in total F4/80+ Kupffer cells was counted and calculated for statistical analysis (N= 3 for each group). a, c, e, g Results are presented as
mean± SEM for each group. ***P< 0.001. NHB non-heart-beating, TUNEL terminal deoxynucleotidyl transferase dUTP nick end labelling
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against apoptosis, regardless of PGE2 inhibition (Fig. 6c).
Thus, MSC-derived PGE2 is a key factor in Kupffer cell
apoptosis inhibition. Furthermore, the paracrine protect-
ive effects of MSCs on Kupffer cells were restricted, not
unlimited, in our in vitro experiments.
MSC-derived PGE2 plays an essential role in inhibiting
Kupffer cell apoptosis by regulating the TLR4-ERK1/2-Fas/
FasL-caspase3 signalling pathway
The accumulation of reactive oxidant species elevates TLR4
expression, activates MAPK-induced NFκB translocation,
Fig. 5 Mesenchymal stem cell (MSC) infusion suppresses serum Th1/Th17 cytokines and chemokines and inhibits intrahepatic inflammatory cell infiltration.
a Serum protein levels of Th1 cytokines (TNFα, IFNγ, and IL2), Th2 cytokines (IL4, IL6, and IL10), Th17 cytokine (IL17), and other pro-inflammatory cytokines
(IL1β and MPO) were measured by immunoassay method (N= 4–6 for each group). b Serum protein levels of CXCL1, CXCL2, CCL2, CCL4, CCL7, and
CXCL10 were detected by immunoassay method (N= 4–6 for each group). c Intrahepatic neutrophil and T-cell infiltration was detected by MPO and CD3
immunohistochemistry staining. Representative images from one experiment are shown at 400× magnification. d MPO- and e CD3-positive cells were
counted for statistical analysis (N= 3 for each group). a, b, d, e Results are presented as mean ± SEM for each group. *P< 0.05, **P< 0.01, ***P< 0.001. CCL
C-C motif ligand, CXCL C-X-C motif ligand, IFN interferon, IL interleukin, MPO myeloperoxidase, NHB non-heart-beating, TNF tumour necrosis factor
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and exacerbates liver injury [37]. Peng et al. have reported
the ability of elevated TLR4 to promote PKCζ-induced cas-
pase3 activation of Kupffer cells [38, 39], and in other re-
ports TLR2 and TLR4 have been found to inhibit
Bcl-2 expression by reducing AKT and ERK1/2 phos-
phorylation [40–43]. Because we demonstrated the
critical role of PGE2 in the protective effects medi-
ated by MSCs, we performed sequential Western blot-
ting to detect related signalling pathways. PGE2
downregulated TLR4, but not TLR2, expression in Kupffer
cells, thus activating ERK1/2 phosphorylation which re-
sulted in the reduced expression of Fas/FasL and cleaved
caspase3 (Fig. 6d and e). Thus, PGE2 inhibits Kupffer cell
apoptosis by regulating the TLR4-ERK1/2-Fas/FasL-cas-
pase3 signalling pathway.
Long-term safety of MSC infusion
The long-term safety of MSC application in vivo is an
inevitable question. To evaluate safety in our study, we
prolonged our observation period of the MSC infusion
group to 3 months. The survival rate at 3 months post-
transplantation was 75%, and all surviving recipients
were healthy with normal serum ALT/AST levels
(Fig. 7a). No tumourigenesis was detected, although two
recipients died because of biliary tract obstruction, as
confirmed by autopsy. Histological examination showed a
relatively normal hepatocellular morphology, obvious cell
infiltration, and mild hyperplasia around the portal area
(Fig. 7b), which may represent a response to ischaemic
biliary injury. Whether these infiltrated cells were inflam-
matory cells, such as neutrophils and T cells, or infused
Fig. 6 Mesenchymal stem cells (MSCs) inhibit Kupffer cell apoptosis via the PGE2-TLR4-ERK1/2-Fas/FasL-caspase3 pathway. Murine-derived
RAW264.7 cells were used to represent Kupffer cells; 5 × 105 macrophages per well were seeded in a six-well plate, and 105 MSCs were seeded in a 0.4-μm
polycarbonate membrane insert Transwell in medium containing or lacking NS-398 (5 μM). After 24 h, the medium was changed once to remove non-
adherent dead cells. After 2 h of incubation at 37 °C without O2, the macrophages were transferred into co-culture with the Transwells containing MSCs,
and 0, 100, 200, 400, or 800 μM hydrogen peroxide (H2O2) was added to specific wells. Then, the co-cultured cells were incubated at 37 °C with 5% CO2 for
6 h to mimic the process of IRI during NHB liver transplantation in vivo. a RAW264.7 cells were stained with F4/80 antibody, a surface marker of Kupffer
cells, and analysed by flow cytometry. Representative images from one experiment are shown. Blue shading and red shading indicate immunofluorescence
intensity of cells for the isotype and F4/80 antibodies, respectively. b In vitro co-culture system. After H2O2 stimulation for 6 hours, apoptosis of Kupffer cells
was detected by Annexin V/PI staining. Representative images from one experiment out of three are shown. c Summarized results are presented as mean
± SEM (N= 3 for each group). d After H2O2 stimulation for 6 hours, expression of TLR2, TLR4, ERK1/2, p-ERK1/2, Fas, FasL, cleaved caspase3, and β-actin from
Kupffer cells was determined by Western blotting analysis. Representative images from one experiment are shown. e Grey value of each band was
calculated by ImageLab software. Representing relative expression of target proteins, the grey value ratio compared with β-actin was analysed and shown
as mean ± SEM (N= 3 for each group). *P< 0.05, **P< 0.01, ***P< 0.001
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MSCs requires further investigation. Our results indicate
that MSC infusion is effective and safe in a mouse model
of NHB liver transplantation.
Discussion
DCDs, formerly known as “non-heart-beating donors”, ex-
hibit notably different pathophysiology from that of brain
death donors. DCDs can be divided into “controlled” and
“uncontrolled” categories according to the Maastricht classi-
fication [44]. Although there has been considerably renewed
interest in DCD donors to increase the pool of available or-
gans, there are challenges associated with the additional
hypoxic damage in DCD grafts, such as the increased inci-
dence of primary non-function, early dysfunction, and cho-
langiopathy in controlled DCD transplantation [5–9].
Additionally, uncontrolled DCD grafts that experience warm
ischaemic time of more than 30 min are excluded from
transplantation worldwide, owing to the higher incidence of
primary non-function, which results in a great loss of do-
nated organs [45].
Innovative strategies and research are needed to
improve the application of DCD liver grafts. However,
animal studies have primarily focused on graft preserva-
tion, including ex vivo machine perfusion and modified
perfusates in rat or swine models [46–50]. To our know-
ledge, only Liu et al. have reported syngeneic liver trans-
plants from DCD mice; however, the surgery in their
study was performed without hepatic artery reconstruc-
tion, which differs from clinical transplant procedures
[51]. To strictly adhere to clinical surgery procedures, we
first attempted liver transplantation from C57Bl/6 to
C57Bl/6 mice; however, because of hepatic artery varia-
tions, the transplant surgery success rate was only ap-
proximately 30%, which was not suitable for establishing
an animal model. Because CBF1 mice have heterosis and
do not reject liver grafts from C57Bl/6 mice, we then
attempted liver transplantation from C57Bl/6 to CBF1
mice. Unexpectedly, the success rate of transplantation
with hepatic artery reconstruction reached 90%, and the
survival rate and graft histology in this mouse model were
consistent (Additional file 1: Figure S1). On the basis of a
large amount of preliminary data, we established an opti-
mal arterialized mouse NHB liver transplantation model
characterized by 10 min of NHB time and 120 min of cold
ischaemic time. The NHB5min group showed no significant
differences compared with the NHB0min group in terms of
serum ALT/AST levels, Suzuki scores, and 14-day survival
rates, thus indicating that warm ischaemia for less than
5 min did not induce obvious graft injury or damage. Ac-
cording to the calculation of Giraud et al. [52], 5 min of
warm ischaemia in mice is equivalent to 42.8 min in
humans. Thus, human DCD liver grafts with a cardiac ar-
rest time of less than 42.8 min may be acceptable, a result
consistent with the clinical criterion that DCD grafts used
within 30 min of warm ischaemia are safe [45]. Further-
more, mRNA levels of pro-inflammatory cytokines associ-
ated with the Th1/Th2 response, with the exception of IL2
and IL4, decreased with increased NHB duration. The
exact mechanism underlying these results remains
unclear, but prolonged NHB time may potentially induce
severe injury or even apoptosis of intrahepatic non-
parenchymal cells, ultimately resulting in decreased
mRNA levels for the majority of Th1/Th2 cytokines.
However, it is unknown why IL2 and IL4 are exceptions
to this trend, and further investigation is required.
MSCs have powerful immunomodulatory and regenera-
tive capacities, thus making them a promising therapeutic
option for treatment of clinical diseases. However, clinical
trials investigating MSCs in liver transplantation are still
in process, and the ultimate effects of MSCs on prolonged
graft survival, reduced transplantation side effects, and
concomitant therapy have yet to be evaluated [53].
In our study, MSC infusion dramatically ameliorated
NHB-induced graft injury and increased recipient
Fig. 7 Mesenchymal stem cell (MSC) infusion is safe and effective with no tumorigenesis detected during 3 months of observation. a At 3 months post-
transplantation, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in the MSC10min group showed no difference compared
with the sham group. Results are presented as mean ± SEM (N= 6 for each group). b Liver grafts were harvested for histological examination and no
tumorigenesis was detected. Haematoxylin and eosin staining of grafts showed relatively normal hepatocellular morphology, cell infiltration, and mild
hyperplasia around the portal area, which may represent a response to ischaemic biliary injury. Representative images are shown at 200× and 400×
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survival post-transplantation. Mechanistically, MSCs
inhibited Kupffer cell apoptosis by producing PGE2 in
an ERK1/2-dependent manner. Together, protected
Kupffer cells and infused MSCs suppressed Th1/Th17
cells, which further decreased chemokine expression and
inhibited inflammatory cell infiltration, thereby resulting
in a reduction in NHB-induced graft injury. Further-
more, 10 min of NHB graft injury was reversed by MSC
infusion. Graft injury in the MSC infusion group was
not significantly different compared with grafts in the
NHB0min group, thus suggesting promisingly clinical ap-
plication of MSCs in uncontrolled DCD grafts. Uncon-
trolled DCD liver grafts with warm ischaemia time of
less than 85.6 min may achieve outcomes comparable to
those of controlled organs if combined with MSC infu-
sion. Additionally, the lack of tumourigenesis observed
during a prolonged observation time of 3 months indi-
cates the safety and effectiveness of MSC infusion. How-
ever, additional clinical studies must be performed to
verify the feasibility of our proposed method.
Kupffer cells, known as liver-resident macrophages,
account for approximately 30% of liver non-parenchymal
cells and more than 50% of resident macrophages
throughout the entire body [54–56] and play an import-
ant role in immunomodulation, phagocytosis, biochem-
ical attack, and liver IRI [57]. Kupffer cells create an
inflammatory milieu by generating cytotoxic ROS, cyto-
kines such as TNFα and IL1β, and neutrophil-associated
chemokines such as CXCL1, CXCL2, CCL2, and
CXCL10 [58–63]. In contrast, IL10 released by Kupffer
cells may induce anergy in T cells and protect tissues
against excessive injury [64, 65].
Interestingly, in our study, the number of F4/80-positive
Kupffer cells decreased rapidly with the extension of warm
ischaemia time, whereas MSC infusion restored Kupffer
cells by inhibiting apoptosis. The protected Kupffer cells
suppressed Th1/Th17 cells and depressed the intrahepatic
infiltration of neutrophils and T cells by reducing cytokine
and chemokine secretion, thus resulting in reduced graft
injury. Moreover, the protective effects of MSCs on NHB
liver grafts were dependent on the presence of Kupffer
cells. Together, our data provide the first evidence of the
extremely important role of Kupffer cells in determining
NHB liver graft quality. In the future, Kupffer cells or F4/
80 expression levels may be valuable in evaluating the
quality of DCD liver grafts and predicting the prognosis of
DCD liver transplantation.
The paracrine effects of MSCs are critical components
of their immunomodulatory functions. Among numerous
soluble factors, PGE2 is the most well-characterized, af-
fecting Th17 differentiation and regulating modulatory
macrophages and dendritic cells [66, 67]. In vitro data re-
vealed the important role of PGE2 in suppressing Kupffer
cell apoptosis. We also elucidated the involvement of the
TLR4-ERK1/2-Fas/FasL-caspase3 signalling pathway in
this process. Notably, the underlying mechanism revealed
in our study broadens insight and allows for a better
understanding of how MSCs protect NHB grafts
(Additional file 2: Figure S2); however, other mechanisms
involved in this protection require further investigation.
Conclusions
In conclusion, we provide the first report of an optimal
arterialized mouse NHB liver transplantation model for
DCD-related research and reveal the profound protective
effects of MSC infusion on NHB liver grafts, which dra-
matically improved recipient survival post-transplantation.
Moreover, we also demonstrate the critical role of PGE2
in inhibiting Kupffer cell apoptosis via the TLR4-ERK1/2-
caspase3 pathway. This work presents a promising and
feasible option for the clinical application of MSC infusion
to protect DCD liver grafts and prolong post-transplant
survival in the future.
Additional files
Additional file 1: Figure S1. C57-CBF1 transplantation showed no
difference in survival and histology compared with C57-C57. (a) Photographs
of NHB mice liver transplantation model. 1: Prolonged hepatic artery of graft;
2: aorta abdominalis of recipient; 3: portal vein reconstruction; 4: inferior vena
cava reconstruction; 5: reconstructed hepatic artery with blood flow. (b) 14-
days survival rate of C57-CBF1 showed no difference compared with C57-C57
(N= 10 for each group, 100% vs. 90%, P= 0.3173), which had a much higher
success rate in hepatic artery reconstruction (90% vs. 30%). (c) Histological
examination of liver grafts in each group at 6 h post-transplantation
(haematoxylin and eosin staining). (d) Suzuki score of graft injury showed no
difference between two groups (1.667 ± 0.2108 vs. 1.833 ± 0.1667, N= 6 for
each group, P= 0.5490). (DOCX 1045 kb)
Additional file 2: Figure S2. Possible mechanisms for MSCs protecting
NHB liver grafts. (a) After NHB liver transplantation, warm and cold
ischemia/reperfusion injury would promote the expression of TLR4 on
the surface of Kupffer cells. TLR4 could inhibit activation of ERK1/2
resulting in elevated expression of Fas/FasL and cleaved-caspase3. These
changes lead to apoptosis of Kupffer cells with a large amount of pro-
inflammatory cytokine and chemokine release. These cytokines and
chemokines promote the inflammatory response and inflammatory cell
infiltration into liver grafts. Finally, aggravated liver graft injury reduced
survival rate after NHB liver transplantation. (b) MSCs could secrete PGE2,
which would inhibit the elevated expression of TLR4 on Kupffer cells after
NHB liver transplantation. Then activated ERK1/2 decreased expression of
Fas/FasL and cleaved-caspase3, resulting in restoration of Kupffer cells.
These changes suppressed Th1/Th17 cytokine and chemokine release,
and reduced neutrophil and T-cell infiltration. Finally, liver grafts of good
quality guaranteed a dramatic increase in the survival rate of recipients.
(DOCX 272 kb)
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